title: Opening the door to follow-on proteins?
abstract: When the FDA approved the follow-on protein Omnitrope in May, it gave generic drug makers the wedge they were hoping for. With pressure building in Washington, did Omnitrope push the door open - or was it just an anomaly?
authors: Stephen
authors: S
authors: Barlas